Industry Overview
The global market for Myo-Inositol 98% has witnessed a compound annual growth rate (CAGR) of 5.8% from 2020 to 2027, with projected expansion continuing as applications diversify into pharmaceuticals, nutraceuticals, and personal care sectors. As an essential nutrient, this compound represents one of the nine biologically significant isomers of inositol with critical roles in cellular signaling and metabolic regulation.
Scientific research demonstrates that Myo-Inositol 98% serves as a precursor for secondary messengers in insulin signal transduction. Its mechanism involves activation of enzymes that modulate glucose uptake and glycogen synthesis, making it particularly valuable in nutritional interventions for insulin resistance conditions.
About Our Company
Shijiazhuang Standard IMP&EXP CO.,LTD. operates as a premier manufacturer and international supplier of premium-grade nutraceutical ingredients. With specialized facilities in Hebei, China, we maintain cGMP compliant production of phyto-chemicals and nutritional supplements, including our flagship product Myo-Inositol 98%.
Contact Information
Phone: 86-311-67665117
Mobile: +8618632125057
Email: info@standard-chem.com
Headquarters
No.448 Heping West Road,
Shijiazhuang, Hebei, China
Product Specifications
Myo-Inositol 98% (C6H12O6) is a white crystalline powder meeting pharmaceutical-grade standards. Our manufacturing utilizes enzymatic conversion technology that ensures optimal stereochemical purity exceeding 98.5%. Particle size distribution is tightly controlled between 80-120 mesh to ensure excellent flow characteristics and dissolution properties.

Technical Parameters
Parameter | Specification | Test Method | Pharma Grade Standard |
---|---|---|---|
Appearance | White crystalline powder | Visual | USP/EP |
Assay (HPLC) | ≥98.0% | HPLC-ELSD | USP/EP |
Loss on Drying | ≤1.0% | Gravimetric (105°C) | USP/EP |
Residue on Ignition | ≤0.1% | Gravimetric (800°C) | USP/EP |
Heavy Metals | ≤10 ppm | ICP-MS | USP/EP |
Melting Point | 224-227°C | DSC | USP/EP |
Specific Rotation | +65.0° to +67.0° | Polarimetry | USP/EP |
Microbiological Parameters | USP 61/62 Compliant | Microbiology | USP/EP |
Key Applications
The high-purity Myo-Inositol 98% is utilized across multiple industries for its biological activity and safety profile:
1. Pharmaceutical Formulations
Used as an active pharmaceutical ingredient (API) in treatments for polycystic ovary syndrome (PCOS), metabolic syndrome, and neuroprotective formulations. Clinical dosing typically ranges from 2-4 grams daily, showing significant improvement in insulin sensitivity markers.
2. Nutritional Supplements
As a premium nutraceutical ingredient in capsule, tablet, and powder formulations. Its recognized role in phosphatidylinositol synthesis makes it valuable in prenatal vitamins and cognitive support formulas.
3. Cosmetic Science
Incorporated at 0.5-2% concentrations in dermal formulations for its hydration properties and ceramide pathway modulation. It improves skin barrier function and reduces transepidermal water loss.
4. Veterinary Applications
Used in livestock nutrition to support metabolic health, particularly in dairy cattle during transition periods where insulin sensitivity decreases. Inclusion at 50-100 g/ton improves milk yield and reproductive parameters.
Quality Assurance
Our Myo-Inositol 98% undergoes rigorous quality control throughout the manufacturing process:
- Identity confirmation via FTIR and NMR spectroscopy
- Purity verification using HPLC with evaporative light scattering detection (ELSD)
- Residual solvent analysis meeting ICH Q3C requirements
- Stability studies conducted under ICH Q1A(R2) guidelines
- Microbiological testing according to USP and
All batches include Certificate of Analysis detailing chromatographic purity, optical rotation, heavy metal content, and microbiological status to ensure compliance with international pharmacopeial standards.
Expert FAQ
Research References
- Unfer V, et al. (2020). "Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials". Endocrine Connections. https://ec.bioscientifica.com/view/journals/ec/9/6/EC-20-0152.xml
- Genazzani AD (2021). "Inositol as putative integrative treatment for PCOS". Reproductive Biomedicine Online. https://www.rbmojournal.com/article/S1472-6483(20)30488-1/fulltext
- Croze ML, Soulage CO (2013). "Potential role and therapeutic interests of myo-inositol in metabolic diseases". Biochimie. https://www.sciencedirect.com/science/article/abs/pii/S0300908413002199
- European Pharmacopoeia Commission (2022). "Myo-Inositol Monograph (01/2022:1270)". EDQM.
- Bevilacqua A, et al. (2020). "Myoinositol in animal nutrition". Animals. https://www.mdpi.com/2076-2615/10/4/701
Request a Quote for Myo-Inositol 98%
Contact Shijiazhuang Standard IMP&EXP CO.,LTD. for premium-grade materials
Inquire NowPost time: Jul - 21 - 2025